dsRNA for treating viral infection
View Patent ↗The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propogation of positive stranded RNA viruses in and between cells.
1. A double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of phosphatidylinositol 4-kinase (PI4K) in a cell, wherein said dsRNA comprises a first strand and a second strand, wherein the sequence of the first strand comprises the sequence of SEQ ID NO: 1.
2. The dsRNA of claim 1 , wherein the sequence of the second strand comprises the sequence of SEQ ID NO: 105.
3. The dsRNA of claim 1 , wherein said dsRNA comprises at least one modified nucleotide.
4. The dsRNA of claim 3 , wherein said modified nucleotide is chosen from the group of: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group.
5. The dsRNA of claim 3 , wherein said modified nucleotide is chosen from the group of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy -modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.
6. A pharmaceutical composition comprising the dsRNA of claim 1 and a pharmaceutically acceptable carrier.
7. A composition comprising the dsRNA of claim 1 , further comprising one or more additional dsRNAs for inhibiting the expression of phosphatidylinositol 4-kinase (PI4K) in a cell.
8. A method for inhibiting the expression of the phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) gene in a cell, the method comprising the steps of:
(a) introducing into the cell a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of phosphatidylinositol 4-kinase (PI4K) in a cell, wherein said dsRNA comprises a first strand and a second strand, wherein the sequence of the first strand comprises the sequence of SEQ ID NO: 1; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the PIK4CB gene, thereby inhibiting expression of the PIK4CB gene in the cell.
9. The method of claim 8 , wherein the sequence of the second strand comprises the sequence of SEQ ID NO: 105.
10. The method of claim 8 , wherein said dsRNA comprises at least one modified nucleotide.
11. The method of claim 8 , wherein said modified nucleotide is chosen from the group of: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group.
12. The method of claim 8 , wherein said modified nucleotide is chosen from the group of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy -modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.
13. A method of treating a pathological process mediated by positive stranded RNA virus infection comprising the step of administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of phosphatidylinositol 4-kinase (PI4K) in a cell, wherein said dsRNA comprises a first strand and a second strand, wherein the sequence of the first strand comprises the sequence of SEQ ID NO: 1.
14. The method of claim 13 , wherein said positive stranded RNA virus is selected from among hepatitis C virus (HCV), human papilloma virus (HPV), and Dengue virus.
15. The method of claim 13 , wherein the sequence of the second strand comprises the sequence of SEQ ID NO: 105.
16. The method of claim 13 , wherein said dsRNA comprises at least one modified nucleotide.
17. The method of claim 13 , wherein said modified nucleotide is chosen from the group of: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group.
18. The method of claim 13 , wherein said modified nucleotide is chosen from the group of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.
19. A vector for inhibiting the expression of the phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) gene in a cell, said vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of the dsRNA of claim 1 .
20. A cell comprising the vector of claim 11 .